Bio-TechneTECH
TECH
About: Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Employees: 3,100
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
547% more call options, than puts
Call options by funds: $5.54M | Put options by funds: $856K
18% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 66
2.82% more ownership
Funds ownership: 98.6% [Q4 2024] → 101.42% (+2.82%) [Q1 2025]
0% more funds holding
Funds holding: 564 [Q4 2024] → 566 (+2) [Q1 2025]
1% less repeat investments, than reductions
Existing positions increased: 201 | Existing positions reduced: 204
17% less funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 5 (-1) [Q1 2025]
17% less capital invested
Capital invested by funds: $11.3B [Q4 2024] → $9.39B (-$1.89B) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$59
2%
upside
Avg. target
$67
15%
upside
High target
$75
29%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Scotiabank Sung Ji Nam | 29%upside $75 | Sector Outperform Maintained | 11 Jul 2025 |
TD Cowen Kyle Bauser | 12%upside $65 | Buy Initiated | 9 Jul 2025 |
Benchmark Robert Wasserman | 29%upside $75 | Buy Reiterated | 5 Jun 2025 |
Wells Fargo Brandon Couillard | 2%upside $59 | Overweight Initiated | 30 May 2025 |
UBS Dan Leonard | 21%upside $70 | Buy Maintained | 9 May 2025 |
Financial journalist opinion
Based on 7 articles about TECH published over the past 30 days
Negative
Seeking Alpha
2 days ago
Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell
Bio-Techne Corporation is a market leader in life science reagents, well positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring revenue, near-term risks from NIH funding cuts and U.S.-China tariffs are not fully priced in. My DCF analysis suggests TECH stock is overvalued, with a fair value of $48 per share versus current high multiples; I initiate with a Sell rating.
Neutral
PRNewsWire
1 week ago
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
MINNEAPOLIS , July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results.
Neutral
Zacks Investment Research
2 weeks ago
INCY or TECH: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Incyte (INCY) or Techne (TECH). But which of these two stocks is more attractive to value investors?
Neutral
Business Wire
2 weeks ago
Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology
WOBURN, Mass.--(BUSINESS WIRE)--Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio's groundbreaking SPEAR UltraDetect™ immunoassays, focusing initially on.
Neutral
PRNewsWire
2 weeks ago
Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection
MINNEAPOLIS , July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau 231 (pTau 231).
Neutral
PRNewsWire
2 weeks ago
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
MINNEAPOLIS , July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout clinical development, Simple Western enabled precise identification and quantification of Collagen VII, a complex therapeutic target critical to ZEVASKYN's potency, supporting lot release testing for the viral vector and the cell therapy in a GMP setting.
Positive
Zacks Investment Research
4 weeks ago
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock
TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
Neutral
PRNewsWire
1 month ago
Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development
MINNEAPOLIS , June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160 antibody therapies against nearly 100 targets and range of diseases have been approved worldwide.
Neutral
PRNewsWire
1 month ago
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.
Negative
Zacks Investment Research
1 month ago
Why Is Techne (TECH) Down 3% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
Charts implemented using Lightweight Charts™